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Abstract
Background: The M235T polymorphism in the AGT gene has been related to an increased risk of hypertension. This finding
may also suggest an increased risk of coronary heart disease (CHD).
Methodology/Principal Findings: A case-cohort study was conducted in 1,732 unrelated middle-age women (210 CHD
cases and 1,522 controls) from a prospective cohort of 15,236 initially healthy Dutch women. We applied a Cox proportional
hazards model to study the association of the polymorphism with acute myocardial infarction (AMI) (n=71) and CHD. In the
case-cohort study, no increased risk for CHD was found under the additive genetic model (hazard ratio [HR]=1.20; 95%
confidence interval [CI], 0.86 to 1.68; P=0.28). This result was not changed by adjustment (HR=1.17; 95% CI, 0.83 to 1.64;
P=0.38) nor by using dominant, recessive and pairwise genetic models. Analyses for AMI risk under the additive genetic
model also did not show any statistically significant association (crude HR=1.14; 95% CI, 0.93 to 1.39; P=0.20). To evaluate
the association, a comprehensive systematic review and meta-analysis were undertaken of all studies published up to
February 2007 (searched through PubMed/MEDLINE, Web of Science and EMBASE). The meta-analysis (38 studies with
13284 cases and 18722 controls) showed a per-allele odds ratio (OR) of 1.08 (95% CI, 1.01 to 1.15; P=0.02). Moderate to large
levels of heterogeneity were identified between studies. Hardy-Weinberg equilibrium (HWE) violation and the mean age of
cases were statistically significant sources of the observed variation. In a stratum of non-HWE violation studies, there was no
effect. An asymmetric funnel plot, the Egger’s test (P=0.066), and the Begg-Mazumdar test (P=0.074) were all suggestive of
the presence of publication bias.
Conclusions/Significance: The pooled OR of the present meta-analysis, including our own data, presented evidence that
there is an increase in the risk of CHD conferred by the M235T variant of the AGT gene. However, the relevance of this
weakly positive overall association remains uncertain because it may be due to various residual biases, including HWE-
violation and publication biases.
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Introduction
Angiotensinogen (AGT) is a liver protein that interacts with
renin to produce angiotensin I, the pro-hormone of angiotensin II.
Angiotensin II is the major effector molecule of the renin-
angiotensin-aldosterone system (RAAS) and plays a key role in the
regulation of blood pressure (BP) by increasing vascular tone and
promoting sodium retention. Genetic variants in the angiotensin-
ogen gene modify the plasma concentration of angiotensinogen,
which has been directly related to arterial blood pressure [1]. The
molecular variant (M235T) of the AGT gene, encoding a threonine
instead of a methionine at residue 235 of the mature protein, has
been associated with a higher plasma AGT level and higher BP in
patients homozygous for the T allele and occurs among various
ethnic populations [1–3]. In a meta-analysis, the TT genotype was
associated with a 32% increase in the risk of hypertension in white
people but not in non-white people, when compared with the MM
genotype [4].
Given the importance of hypertension in the occurrence of
coronary heart disease [5], this finding suggests that this
polymorphism may be related to increased risk of CHD. A few
studies [6–8], including recent publications, [9,10] have found that
there is an association of the M235T AGT variant with increased
CHD risk; however, this relationship was not confirmed in several
other studies [11–13] as well as in a meta-analysis [14]. Marked
ethnic differences in the frequency of the T allele, small sample
PLoS ONE | www.plosone.org 1 June 2008 | Volume 3 | Issue 6 | e2533sizes and genotyping or phenotyping errors could partly account
for discrepancies among these gene-disease association studies.
Therefore, we investigated the association of the M235T
polymorphism in the AGT gene (National Center for Biotechnol-
ogy Information single nucleotide polymorphism cluster ID rs699)
with acute myocardial infarction (AMI) and CHD in a large
population-based cohort of middle-aged Dutch women and
conducted an updated meta-analysis of the available studies to
clarify the role of the M235T polymorphism in CHD risk.
Methods
Case-cohort study
Study design, general questionnaire, anthropometric and
laboratory measurements have been described in detail elsewhere
[15–16]. Briefly, the study population consisted of participants of
the Prospect-EPIC cohort. Participants were recruited between
1993 and 1997 among women living in Utrecht and the vicinity
who attended the regional population-based breast cancer-
screening program. A total of 17,357 women, aged 49–70, were
included. At baseline, a general and a dietary questionnaire were
administered, a limited physical examination was performed and a
non-fasting blood sample was taken. Follow-up event information
was obtained from the Dutch Centre for Health Care Information,
which holds a standardized computerized register of hospital
discharge diagnoses. Using the International Classification of
Diseases, ninth Revision (ICD-9) codes for the main discharge
reason, we categorized cardiovascular disease (codes 390–459) as
CHD (codes 410–414), including AMI (code 410), and other
cardiovascular diseases. Whenever multiple events (AMI and
CHD) occurred, the first occurrence of that endpoint was taken as
the endpoint of interest in endpoint-specific analyses. All women
signed an informed consent form prior to study inclusion. The
study was approved by the Institutional Review Board of the
University Medical Center Utrecht.
We applied the case-cohort design introduced by Prentice [17].
From the 17,357 women in the total cohort, we randomly selected
a sample of 10% as the sub-cohort (n=l736). Women who did not
consent to linkage with vital status registries or who were not
traceable (cases n=3/sub-cohort n=38) were not included.
Women who reported a diagnosis of cardiovascular disease
(ICD-9; 390–459) at baseline or who had missing questionnaires,
blood, or DNA samples were excluded. This resulted in 15,236
women in the total cohort and 1522 women in the sub-cohort (as
the control group) at baseline. All individuals with first fatal and
non-fatal CHD and ischemic stroke events that arose during
follow-up until January 1
st 2000 were selected as cases. These were
211 CHD cases, including 71 AMIs. For all case subjects, follow-
up ended at the date of diagnosis or at the date of death due to
cardiovascular disease.
Genetic analysis. Genetic analysis was performed at the
Cardiovascular Genotyping (CAGT) laboratory of the
Department of Internal Medicine of the University Hospital
Maastricht. Genomic DNA was extracted from buffy coats using
the QIAampH Blood Kit (Qiagen Inc., Valencia, California, USA).
Genotyping of the polymorphisms was performed using a
multilocus genotyping assay for candidate markers of
cardiovascular disease risk (Roche Molecular Systems Inc.,
Pleasanton, CA, USA) [18]. Briefly, each DNA sample was
amplified using two multiplex polymerase chain reactions, and the
alleles were genotyped simultaneously using an array of
immobilized sequence-specific oligonucleotide probes. This array
of probes was blotted on plastic strips, and, after staining,
genotypes were scored based on blue (positive) and white
(negative) bands. Each blue band, representing a specific
genotype, was scored by specific software (counting the pixel
intensity of each band) and checked manually. Genotyping was
performed blinded to the case-control status. A random double-
check was performed to detect potential genotyping errors in a
subset of 100 samples. The check confirmed the previous
genotyping results by 100%.
Data analysis. Hardy-Weinberg equilibrium (HWE) was
tested with the x
2 test among the controls. Allele frequencies
were estimated by gene counting. We used the ANOVA F test to
estimate relationships among the M235T genotypes and
continuous variables, while we tested the significance of any
difference in proportions by applying the x
2 statistic. A p-value
,0.05 (2-sided) was considered statistically significant.
To assess the relationship of the M235T polymorphism in the
AGT gene with the outcome, we used a Cox proportional hazards
model with an estimation procedure adapted for case-cohort
designs. We used the unweighted method by Prentice [17,19],
which is incorporated in a SAS macro at http://lib.stat.cmu.edu/
general/robphreg. A previous meta-analysis [14] showed that the
effect of the AGT M235T variant on its intermediate phenotype
(plasma angiotensinogen level) follows an additive model accord-
ing to the number of T alleles [5% (95% CI: 2 to 8%) increase for
the MT and 11% (95% CI: 7 to 15%) increase for the TT
genotype versus the MM genotype]. Therefore, our priori
hypothesis was that the association between the M235T
polymorphism in the AGT gene and CHD follows an additive
model according to the number of T alleles. However, other
genetic models were evaluated as well. We considered different
modes of inheritance as follows: the additive ‘‘per-allele’’ model, the T
allele was compared between cases and controls by assigning
scores of 0, 1, and 2 to homozygotes for the M allele,
heterozygotes, and homozygotes for the T allele, respectively; the
recessive model, the TT genotype versus the MT and MM combined
genotypes; and the dominant model, the MT and TT genotypes
combined versus the MM genotype. We also performed separate
pairwise comparisons of the MT and TT genotypes versus the
MM genotype.
Meta-analysis
Searching. We searched PubMed/MEDLINE, Web of
Science, and EMBASE up to February 2007 for observational
studies evaluating an association between the M235T
polymorphism in the AGT gene and CHD. Terms used for the
search contained both medical subject heading terms and text
words: (Met235Thr OR M235T OR T704C) AND
(angiotensinogen OR AGT) AND (polymorphism OR mutation
OR genetic OR genotype) AND (‘‘coronary disease’’ OR
‘‘coronary heart disease’’ OR CHD OR ‘‘myocardial infarction’’
OR MI OR ‘‘myocardial infarct’’ OR ‘‘coronary artery disease’’
OR CAD OR ‘‘ischemic heart disease’’ OR IHD OR
‘‘cardiovascular disease’’ OR ‘‘heart disease’’ OR angina). We
also retrieved additional studies by hand searching the
bibliographies of original research reports and review articles
and through the MEDLINE option ‘‘related articles’’. Search
results were limited to articles published in English and studies on
human subjects.
Selection. All studies were considered potentially eligible if
they aimed to investigate the relationship between the M235T
genotypes and risk of CHD or MI. Any observational study,
regardless of sample size, which fulfilled the following criteria, was
included: (i) AGT M235T genotype frequencies were provided by
case-control status (studies without controls were excluded); (ii) risk
of CHD or MI was evaluated (studies on recurrent coronary events
AGT M235T Variant and CHD
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effect size and its 95% CI; (iv) non-overlapping data were
contained. For duplicate publications, the study with the smaller
data set was excluded.
Data abstraction. The following information was extracted
from each study that we included: the first author’s name; country;
year of publication; the population evaluated; study design; mean
age or age range for case-patients and controls; definition and
number of cases and controls; allele frequencies and genotype
distribution in case-patients and controls (where data were not
given, they were calculated from the corresponding genotyping
frequencies of the case and control groups); consistency of
genotype frequencies with HWE (calculated); gender in the
evaluated population and male percentage, matching variables,
use of blinding of genotyping staff, performing regenotyping of a
random sample, and crude ORs and 95% CIs for development of
CHD or MI related to the AGT gene genotypes based on different
genetic models (from the original paper or calculated from crude
data if not provided). We again considered a dominant, a
recessive, an additive ‘‘per-allele’’ model and pairwise
comparisons. Data were extracted independently and entered
into separate databases by two authors (performed by MHZ and
MLB). Results were compared, and disagreements were resolved
by a consensus.
Quantitative data synthesis. The method of Mantel-
Haenszel was used to calculate the odds ratio for the pooled
data in a fixed-effects model, and, if there was evidence for
heterogeneity, the DerSimonian-Laird method was used for the
pooled odds ratio in a random-effects model, under pairwise
comparisons of the different genotypes and dominant, recessive,
and additive inheritance models. For all the models used, the T
allele was considered the risk allele. The genetic model to be
considered as the priori hypothesis was the additive model. In each
study, we tested for HWE by using the x
2 test or an exact test
among the controls by using the genhwi command in Stata 9.2
[20].
In addition, we used Cochran’s x
2 – based Q statistic for
between-study heterogeneity, which is considered to be significant
for P,0.10, as well as the I
2 statistic for estimation of inconsistency
in meta-analyses [20]. I
2 represents the percentage of the observed
between-study variability due to heterogeneity rather than to
chance. It ranges between 0% and 100%, where a value of 0%
indicates no observed heterogeneity, and larger values indicate an
increasing degree of heterogeneity (roughly suggested cut-off
points include: I
2=0–25%, no heterogeneity; I
2=25–50%,
moderate heterogeneity; I
2=50–75%, large heterogeneity;
I
2=75–100%, extreme heterogeneity) [21].
We used funnel plots to examine the publication bias of
reported associations. We also used Egger’s test and the Begg-
Mazumdar test with 95% CI for evaluation of publication bias,
which are considered to be significant for P,0.10. Meta-analysis
was carried out using STATA 9.2. We used random effect meta-
regression models with restricted maximum likelihood estimation
to evaluate the extent to which different variables explained
heterogeneity among the individual ORs. The pre-specified
characteristics for assessment of sources of inter-study heteroge-
neity were: study size (for detailed definition see [22]); ethnicity of
population evaluated (of Caucasian descent, East Asian, and
others); male percentage in each study, matching (matched or
unmatched); blinding of genotyping staff (blinded, or not
reported); performing regenotyping of a random sample (per-
formed or not reported); violating HWE (violated or confirmed;
the term ‘‘violated’’ used for statistically significant deviation of
HWE) in sub-group analysis as well as in meta-regression analysis.
HWE Correction. For evaluating the impact of HWE-
violated studies on effect estimates (at the 0.05 significance level)
under different genetic models, odds ratios, and variances were
corrected by using the HWE-predicted genotype counts in the
control instead of the observed counts as previously suggested [20].
Thereafter, they were included in the sensitivity analysis.
Results
Prospect-EPIC study results
The general characteristics of the randomly sampled partici-
pants of the cohort (N=1522) are given in Table 1. The genotype
distribution was in Hardy-Weinberg equilibrium (x
2=0.020;
P=0.89). General and clinical characteristics of CHD cases and
controls are shown in Table 1. The median follow up time for the
random sample was 4.3 years, with a total of 6,523 person years.
The actual follow-up in the baseline cohort of 15,236 women was
64,768 person years. Due to the case-cohort design, 23 women in
the sub-cohort eventually were CHD cases (among which there
were nine AMI cases).
Due to the association of the M235T genotypes with some risk
factors of CHD, we presented crude models and models adjusted
for hypertension, total cholesterol and waist to hip ratio as
potential confounding factors. Table 2 presents hazard ratios of
AMI and CHD under different genetic models. Under the additive
model of inheritance, no increased risk for CHD was found
(HR=1.20; 95% CI, 0.86 to 1.68; P=0.28), which did not alter
after adjustment (HR=1.17; 95% CI, 0.83 to 1.64; P=0.38). The
same was true for other comparisons (Table 2). Analyses for AMI
risk did not show any statistically significant associations (Table 2).
Meta-Analysis results
Flow of included studies. A total of 44 gene-disease
association studies, including the present study, evaluating the
AGT M235T gene variant and CHD risk were identified. Seven
articles were excluded, three of which were duplicate publications
[12,23,24], three of which did not provide relevant data [25–27],
and one of which studied the risk of recurrent coronary events
[28]. Finally, 37 studies met the selection criteria. In one paper,
the provided results were based on two different studies [6], so
both were included in the meta-analysis. Therefore, 38 studies
with 13,284 cases and 18,722 controls were included in the final
meta-analysis (Figure 1).
Study characteristics
Characteristics of the studies are shown in Table 3 [6–
8,10,11,13,29–58]. There were 25 studies in Caucasians, eight
studies in East Asians, and five studies in other populations (West
Asian, South Asian, African, African-American, and South
American). The last was collapsed into a miscellaneous group.
The design of the studies was case-control, except for three studies
that were prospective cohort [56], case-cohort (present study), and
cross-sectional [40]. The T allele frequency varied from 26 to 54
percent in Caucasians, 65 to 91 percent in East Asians, and 34 to
83 percent in the miscellaneous group.
All studies used polymerase chain reaction methods for
genotyping, and most used a restriction fragment length method
for polymorphism analysis. Blinding of investigators involved in
genotyping with respect to the case/control status of the
participants was reported in six studies [8,32,50,51,56]. A random
double-check to detect potential genotyping errors was mentioned
in five studies [37,50,53,56]. In most of the studies, the genotype
frequencies were consistent with HWE. However, statistically
significant deviations from HWE were found in five studies
AGT M235T Variant and CHD
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the Prospect –Epic cohort.
Characteristics sub-cohort (N=1522) P-value
b CHD cases Sub-cohort P-value
c
M235M M235T T235T
N total (%) 535 (35.2) 737 (48.4) 250 (16.4) - 210 1522 -
Age at intake (yr)
a 57.165.8 57.166.2 57.466.3 0.83 60.565.9 57.166.1 ,0.01
Body mass index (kg/m
2)
a 26.064.1 25.663.8 25.864.1 0.19 26.863.9 25.864.0 ,0.01
Weight (kg)
a 70611 69611 69611 0.17 71611 69611 0.07
Height (cm)
a 164.465.9 164.266.0 164.066.1 0.66 162.866.0 164.366.0 ,0.01
Waist to hip ratio
a 0.79460.057 0.78660.058 0.78660.055 0.03 0.81360.060 0.78960.057 ,0.01
Hypertension (%)
d 39.4 41.2 48.4 0.06 60.5 41.8 ,0.01
Systolic blood pressure (mm Hg)
a 131619 133621 135620 0.07 143622 133620 ,0.01
Diastolic blood pressure (mm Hg)
a 79610 79611 80611 0.14 82611 79611 ,0.01
Presence of diabetes (%) 2.2 2.0 2.8 0.78 5.7 2.2 ,0.01
Presence of hypercholesterolemia (%) 3.6 4.6 2.8 0.38 11.4 3.9 ,0.01
Current alcohol consumption (%) 88.7 87.1 89.2 0.60 80.7 88.0 ,0.01
Smoking status (%) Past 35.1 33.8 36.4 0.73 26.2 34.7 0.02
Current 23.2 22.4 23.6 0.90 33.8 22.9 ,0.01
Pack- years
e 6.869.5 6.569.5 6.769.3 0.87 9.7611.4 6.769.5 ,0.01
Total cholesterol (mmol/L)
a 5.961.0 5.860.9 5.961.1 0.05 6.461.0 5.961.0 ,0.01
HDL cholesterol (mmol/L)
a 1.660.4 1.660.4 1.660.4 0.33 1.460.3 1.660.4 ,0.01
LDL cholesterol (mmol/L)
a 4.061.0 3.960.9 3.960.9 0.25 4.461.0 3.960.9 ,0.01
Serum glucose (mmol/L)
a 4.661.5 4.561.3 4.561.2 0.52 5.162.5 4.561.4 ,0.01
HDL, high-density lipoprotein; LDL, low-density lipoprotein; CHD, coronary heart disease (ICD 410–414).
aMean6standard deviation.
bComparison of risk factors across genotypes, using the ANOVA F test (continuous variables) and the x
2 statistic (categorical variables).
cComparison of risk factors across disease status, using the independent samples t-test (continuous variables) and the x
2 statistic (categorical variables).
dDefined as a systolic blood pressure $140 mm Hg and/or diastolic blood pressure $90 mm Hg and/or questionnaire positive.
eThe number of packs of cigarettes smoked per day by the number of years the person has smoked.
doi:10.1371/journal.pone.0002533.t001
Table 2. Association of the AGT M235T polymorphism and AMI and CHD under different genetic models.
Mode of Inheritance Crude: model 1 Adjusted: model 2
b
Hazard ratio 95% CI P-value Hazard ratio 95% CI P-value
AMI
Additive
a 1.20 0.86–1.68 0.28 1.17 0.83–1.64 0.38
Recessive (TT vs. M-carriers) 0.77 0.43–1.41 0.40 0.87 0.46–1.58 0.62
Dominant (T-carriers vs. MM) 0.79 0.47–1.32 0.36 0.79 0.46–1.33 0.37
MT vs. MM 1.09 0.84–1.41 0.53 1.11 0. 85–1.45 0.45
TT vs. MM 1.21 0.86–1.70 0.28 1.17 0.83–1.63 0.38
CHD
Additive
a 1.14 0.93–1.39 0.20 1.11 0.90–1.38 0.33
Recessive (TT vs. M-carriers) 0.87 0.60–1.26 0.45 0.98 0.66–1.47 0.93
Dominant (T-carriers vs. MM) 0.82 0.60–1.12 0.21 0.80 0.58–1.10 0.18
MT vs. MM 1.09 0.93–1.27 0.31 1.13 0.95–1.34 0.16
TT vs. MM 1.14 0.93–1.40 0.20 1.11 0.90–1.37 0.33
AMI=acute myocardial infarction (ICD 410); CHD=coronary heart disease (ICD 410–414).
aThe additive genetic model assumes that there is a linear gradient in risk between the MM, MT and TT genotypes (MM genotype baseline). This is equivalentt oa
comparison of the T allele versus the M allele (baseline).
bWe used a cox proportional hazards model with an estimation procedure adapted for case-cohort designs; adjusted for waist to hip ratio, hypertension, total
cholesterol.
doi:10.1371/journal.pone.0002533.t002
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as a .50% stenosis of at least one coronary vessel
[7,8,10,11,34,40,41,43,46,48,50,51,54–57], while, in four studies,
a .70% stenosis was considered [36,42,52,58]. In 14 studies
[13,29–32,35,37–39,44,47,49,53], the WHO criteria were used,
and, in four studies, CHD was diagnosed based on a clinical
diagnosis [6,33,45]. Controls arose from the source population of
the cases in 21 studies [6,8,13,29,31–33,35–38,45,47,49–53,55],
while hospital-based/not population-based controls were used in
17 studies [7,10,11,30,34,39–44,46,48,54,56–58].
Quantitative data synthesis
The overall OR under a random-effects model using an additive
model for CHD risk was 1.08 (95% CI, 1.01 to 1.15; P=0.025;
Figure 2). However, there was evidence of substantial between-
study heterogeneity (I
2=55.5%, P,0.001). Table 4 shows the
association of the AGT T235M polymorphism with CHD risk
under different genetic contrasts. When a recessive model was
evaluated, a significant association was found between individuals
homozygous for the T allele (T235T genotype) and CHD risk,
when compared to carriers of the M allele (OR=1.11; 95% CI,
1.02 to 1.22; P=0.016). Under the dominant model, the
association was not significant. Under pairwise comparisons, there
was a significant modest association between the T235T genotype
and CHD risk, as compared with the M235M genotype
(OR=1.15; 95% CI, 1.00 to 1.32; P=0.045). There was evidence
for moderate to large between-study heterogeneity under all
models (Table 4). Sub-group analysis, by study characteristics
under the additive model, showed that matching, blinding of
genotyping staff, and regenotyping of a random sub-sample
explained little of the heterogeneity. However, stratification
showed an attenuated effect estimates in the large studies, in
studies that CHD was defined based on angiography or WHO
criteria, and in particular in studies that were in HWE (Table 5).
Further evaluation of potential sources of the heterogeneity was
performed using a meta-regression analysis.
Meta-regression
First, an empty regression was run with only the log of the effect
estimate of pooled studies under the additive model to determine
the baseline value for t
2, an estimate of between-study variation
(baseline t
2=0.025). Next, single covariates were added in a series
of univariate models. We performed the regression analysis for ten
pre-defined potential sources of heterogeneity, including ethnicity,
sex, mean age of cases, study size, case definition, source of
controls, HWE-violation, blinding in genotyping, performing a
sub-sample regenotyping, and matching (we hypothesized that
studies that used matching might produce more conservative
estimates of association). Univariate regression analyses showed
that violation of HWE (b coefficient=0.27 (0.06 to 0.48);
PHet=0.015, t
2=0.019), the mean age of cases (b=20.01
(20.02 to 0.0008); PHet=0.066, t
2=0.024), and the method of
case definition, clinically diagnosed CHD versus WHO criteria
adjusted for other definitions (b=0.26 (0.02 to 0.50); PHet=0.038,
t
2=0.020), were significant sources of heterogeneity among
studies. The study size (PHet=0.241, t
2=0.024), the ethnicity
(PHet=0.591, t
2=0.025), the male percentage in the study
(PHet=0.701, t
2=0.029), blinded genotyping (PHet=0.890,
Figure 1. Flow chart of study selection.
doi:10.1371/journal.pone.0002533.g001
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2=0.026), sub-sample regenotyping (PHet=0.131, t
2=0.023), the
source of controls (PHet=0.640, t
2=0.025), and matching
(PHet=0.942, t
2=0.026) were not significant sources of heteroge-
neity among studies. Violation of HWE in multivariable regression
analysis remained a statistically significant source of heterogeneity
after adjustment for the effect of study size (PHet=0.031,
t
2=0.020). Adding the mean age of cases and method of case
definition to the model with violation of HWE decreased the t
2
value to 0.017 (PHet=0.073 for violation of HWE, PHet=0.057 for
the mean age of cases, and PHet=0.162 for clinically diagnosed
CHD). It also showed that the effect of method of case definition
on the variation among the studies was through the effect of the
mean age on the heterogeneity and not as an independent factor.
A model that included only violation of HWE and the mean age of
cases reduced the t
2 value to 0.018 (PHet=0.019, and 0.052,
respectively).
Sensitivity Analysis
First, the influence of deviation from the HWE on effect
estimates was examined by using HWE-deviated adjusted ORs.
Table 6 presents the genotype-based contrasts with corrected
ORs, as well as the allele-based contrast. After adjustment, a
smaller overall effect was seen under the additive, dominant, and
pairwise comparisons. Moreover, after adjustment, the previously
significant association under the additive model, as well as the TT
vs. MM comparison, was no longer statistically significant. The
association under the recessive model still remained significant.
Figure 3 shows a funnel plot in which the log of the OR of CHD
risk under the additive genetic model was plotted against the
standard error of the log of the OR in each study. The funnel plot
for the overall results was substantially asymmetric for small
negative studies. Moreover, tests for potential publication bias
(The Egger’s test and the Begg-Mazumdar test; P-values equal to
0.066 and 0.074, respectively) suggested the presence of a
publication bias. By using the trim and fill method, we showed
that, if the publication bias was the only source of the funnel plot
asymmetry, it needed seven more studies to be symmetrical
(Figure 4).
Discussion
Prospect-EPIC study
In this prospective study of healthy women aged 49 to 70 years,
we investigated the relationship between the M235T polymor-
phism in the AGT gene and risk of AMI and CHD later in life.
Under the additive genetic model, increased risks, albeit not
statistically significant, were found for the incidence of AMI and
CHD, which did not alter after adjustment. Likewise, we did not
find a clear association between the variant and risk of CHD or
AMI using different genetic models. This may be explained by: (i)
the absence of a biological effect, (ii) the presence of real genetic
heterogeneity according to ethnic background, or (iii) failure to
detect a small effect because the epidemiologic risk for an
individual genetic variant is likely to be small and a large sample
size is needed for adequate statistical power. It has been commonly
proposed that, as well as a need for much larger and more rigorous
studies those that are currently used, there is a greater need for
international collaborations, particularly for a complex disease like
CHD [59].
Strengths and limitations. In our study, the data collection
was prospective, before the diagnosis of AMI or CHD and equal
for all participants. This ensures that the cases and the randomly
selected controls are comparable [17]. For a multifactorial trait,
like CHD, this provides a valid approach to evaluate the
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CHD, while taking into account co-existing and risk-modifying
factors. In this study, prevalent cases of CHD were excluded from
the analyses to prevent introducing bias due to potentially selective
survival. The Prospect study was a population-based cohort, which
makes it less susceptible to selection bias. Additional strengths were
the comprehensiveness of our data and sample collection, as well
as the morbidity and mortality follow-up for the entire cohort
Figure 2. Results of published studies of association between the M235T polymorphism in AGT gene and coronary heart disease in
different ethnic groups. ORs for the outcome compared the T235 allele vs. the M235 allele (Additive model). The size of the box is proportional to
the weight of the study. Given P-values for odds ratios are based on DerSimonian-Laird method using a random effects model and for heterogeneity
in different ethnic groups are based on Q-test.
doi:10.1371/journal.pone.0002533.g002
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design of the study combined the advantages of cohort studies
(multiple outcomes and time-dependent covariates) with those of
case-control analyses (fewer subjects); thus, it was more efficient
than cohort studies. Classical case-control studies might be affected
by selection bias since only non-fatal cases can be included, which
was not the case in this study because of our endpoint definition.
Moreover, we did not have misclassification of exposure
(genotypes), which, when present, generally lead to a bias
toward the null because we used standard laboratory protocols,
Table 4. ORs and 95% CI for coronary heart disease and the M235T polymorphism in AGT gene under different genetic models.
Genetic model
Random effects
OR (95% CI) P-value I
2 (%) (95% CI)
Q statistic for
heterogeneity (df=37)
P-value for
heterogeneity
Egger’s test
P-value
Begg’s test
P-value
Additive
a 1.08 (1.01–1.15) 0.025 55.5 (36–69) 83.21 ,0.001 0.066 0.074
Recessive (TT vs. M-carriers) 1.11 (1.02–1.22) 0.016 37.5 (7–58) 59.23 0.012 0.011 0.070
Dominant (T-carriers vs. MM) 1.07 (0.96–1.19) 0.253 56.0 (37–69) 84.02 ,0.001 0.549 0.706
MT vs. MM 1.02 (0.91–1.14) 0.724 51.3 (29–66) 75.99 ,0.001 0.895 0.960
TT vs. MM 1.15 (1.00–1.32) 0.045 53.3(33–68) 79.30 ,0.001 0.286 0.615
aThe additive genetic model assumes that there is a linear gradient in risk between the MM, MT and TT genotypes (MM genotype baseline). This is equivalentt oa
comparison of the T allele versus the M allele (baseline).
doi:10.1371/journal.pone.0002533.t004
Table 5. Studies of the M235T polymorphism in AGT gene and risk of coronary heart disease under additive model grouped by
study characteristics.
Study characteristics
Number of
studies
Per-allele OR
(95%CI) P-value I
2 (%) (95%CI)
Q statistic for
heterogeneity
P-value for
heterogeneity
Overall 38 1.08 (1.01–1.15) 0.025 55.5 (36–69) 83.21 ,0.001
Study size
Small 26 1.12 (1.02–1.24) 0.021 50.2 (35–73) 50.24 0.002
Large 12 1.03 (0.95–1.12) 0.502 62.0 (29–80) 28.92 0.002
Ethnicity
Caucasians 25 1.08 (1.01–1.17) 0.028 58.2 (35–73) 57.43 ,0.001
Eastern Asians 8 1.12 (0.89–1.40) 0.325 69.5 (36–85) 22.96 0.002
Others 5 0.99 (0.84–1.18) 0.944 0.00 (0–79) 2.31 0.679
Matching
Matched 11 1.07 (0.96–1.18) 0.211 26.2 (0–63) 13.56 0.194
Unmatched 27 1.08 (0.99–1.17) 0.072 62.7 (44–75) 69.65 ,0.001
Violating HWE
Violated 5 1.38 (1.05,–1.83) 0.022 70.7 (26–88) 13.65 0.009
Confirmed 33 1.04 (0.98–1.11) 0.188 43.5 (5–63) 56.66 0.005
Blinding of genotyping staff
Blinded 6 1.07 (0.92–1.24) 0.391 62.6 (9–85) 13.36 0.020
Not reported 32 1.08 (1.00–1.16) 0.040 55.5 (34–70) 69.88 ,0.001
Regenotyping of a random subsample
Performed 5 0.94 (0.79–1.14) 0.544 58.9 (0–85) 9.74 0.045
Not reported 33 1.10 (1.03–1.18) 0.007 54.7 (33–69) 70.64 ,0.001
Case definition
.50%stenosis of $1 major vessels 16 1.09 (0.97–1.23) 0.135 62.4 (35–78) 39.9 ,0.001
.70%stenosis of $1 major vessels 4 1.10 (0.90–1.34) 0.358 40.7 (0–80) 5.1 0.167
WHO criteria 14 1.00 (0.93–1.09) 0.942 36.9 (0–67) 20.6 0.081
Clinical diagnosis 4 1.31 (1.15–1.49) ,0.001 0.00 (0–85) 2.7 0.439
Source of controls
Population-based 21 1.09 (1.01–1.19) 0.036 62.6 (40–77) 53.5 ,0.001
Hospital-based 17 1.05 (0.95–1.17) 0.354 44.6 (2–69) 28.9 0.025
doi:10.1371/journal.pone.0002533.t005
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errors, and had our AGT genotypes in Hardy-Weinberg
equilibrium. The limitations of this study were the relatively
short period of follow-up and the small number of cases.
Moreover, because this cohort was exclusively composed of
Dutch women, these results cannot be generalized to men or
other ethnic groups, for whom the rates of the events or the allele
frequency are known to differ.
Meta-Analysis
The current meta-analysis, which includes new data from a
prospective study in a large population-based cohort of Dutch
women, represents a comprehensive evaluation of the M235T
variant of the AGT gene in CHD risk. Although a pooled per-allele
OR was suggestive of a modest increase in the risk of CHD of 1.08
(95% CI, 1.01 to 1.15), the robustness of this summary estimate is
uncertain. First, in the pre-specified sub-groups analyses in the
meta-analysis, larger studies, those with validated genotyping
quality controls, and studies that used standardized criteria for
case definition did not provide strong evidence for a positive
statistically significant association between the M235T variant of
the AGT gene and CHD risk. Second, the meta-regression analysis
revealed that the HWE violation was a significant source of the
moderate to large heterogeneity in the meta-analysis. Taking
violation of HWE into account in the meta-analysis decreased the
overall effect (Table 5). Third, the previous result was confirmed
by using HWE-deviation adjusted ORs in the meta-analysis
Figure 3. Begg’s funnel plot with pseudo 95% confidence limits under the additive genetic model. The size of the circle is proportional
to the weight of the study.
doi:10.1371/journal.pone.0002533.g003
Table 6. ORs and 95% CI after adjustment for HWE-deviation under different genetic models.
Genotype
contrasts Population
Number of
studies Random effects model I
2 (%) (95%CI)
Q statistic for
heterogeneity
P-value for
heterogeneity
Odds ratio 95%CI P-value
Additive All 38 1.11 0.81–1.53 0.522 0 (0–37) 2.04 1.000
Caucasians 25 1.11 0.75–1.64 0.616 0 (0–44) 1.04 1.000
East Asians 8 1.19 0.60–2.36 0.626 0 (0–68) 0.82 0.997
Recessive All 38 1.14 1.04–1.26 0.007 56 (37–70) 84.66 ,0.001
Caucasians 25 1.15 1.03–1.29 0.014 56 (32–72) 55.02 ,0.001
East Asians 8 1.18 0.90–1.55 0.242 73 (45–87) 26.15 ,0.001
Dominant All 38 1.05 0.96–1.15 0.330 49 (26–65) 72.52 ,0.001
Caucasians 25 1.08 0.98–1.20 0.121 58 (35–73) 57.82 ,0.001
East Asians 8 0.92 0.64–1.33 0.656 33 (0–70) 10.41 0.166
MT vs MM All 38 1.00 0.92–1.09 0.996 15 (0–43) 43.41 0.217
Caucasians 25 1.03 0.94–1.14 0.497 25 (0–54) 31.99 0.127
East Asians 8 0.82 0.60–1.11 0.204 0 (0–68) 6.53 0.480
TT vs MM All 38 1.13 0.99–1.28 0.080 52 (31–67) 77.88 ,0.001
Caucasians 25 1.19 1.02–1.38 0.023 60 (38–74) 60.11 ,0.001
East Asians 8 1.01 0.65–1.59 0.952 50 (0–77) 13.87 0.054
doi:10.1371/journal.pone.0002533.t006
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meta-analysis. Taken together, these findings point to a violation
of HWE and publication biases as the potential explanations for
the results observed in the meta-analysis.
Some aspects of the current meta-analysis need to be considered
to appreciate the findings. First, it might not be very practical to
adjust for violation of HWE in the studies that mentioned that the
violation is not due to genotyping errors. However, in the current
meta-analysis, the HWE-violated studies that were included in the
pooled estimate did not provide any reason for the violation.
Therefore, we performed sensitivity analyses by using HWE-
adjusted ORs and corresponding variances. Thereafter, a smaller
overall effect was seen under most of the genetic models. Second,
the power of tests for HWE and the power to detect genotyping
errors are low. Therefore, the inability to detect a deviation from
the HWE does not mean that there is no deviation, nor does it rule
out the presence of genotyping errors, especially for small sample
sizes. Third, our meta-analysis was based on published studies and
we did not have access to the original data. However, it could be
possible that an association between the genotype and disease
exists in certain contexts rather than in all people studied. For
example, a case-control study showed that the TT genotype was
associated with an increased risk of CHD and MI only in smokers
[33]. Finally, in all meta-analyses of gene-disease association
studies, the inclusion criteria of cases and controls can be a
potentially confounding factor. In this meta-analysis, cases were
well defined and the source of controls was not a significant source
of variation. However, the advantages of this study were the large
sample size of the meta-analysis of 38 studies with 13284 cases and
18722 controls, which was twice the number of studies and sample
sizes that had been reported in the previous meta-analysis [14], the
exploration of potential sources of heterogeneity in the meta-
analysis, and the evaluation of the association under different
modes of inheritance.
Approximately 10% of gene-disease association studies are
affected by statistically significant deviation from HWE, which
could result from genotyping error, chance, inbreeding, non-
random mating, differential survival of marker carriers, genetic
drift, population stratification, or a combination of these reasons
[20,60]. Of these, genotyping error could be avoided by using
standard genotyping methods and performing quality assessment. It
has been recommended that authors specify the quality measures
forthegenotypinganalysis,suchasthe blindingoflaboratorystaffto
the donor subjects and hypotheses being investigated, procedures
for establishing duplicates, degree of reproducibilitybetween quality
control replicates, and the inspection for conformity to HWE [61].
In the current meta-analysis, in studies where the blinding of
genotyping staff was not reported, a statistically significant increased
risk of CHD was found, while those that used blinding methods did
not find a significant association. Moreover, for studies without
regenotyping of a random sub-sample, a significant increase in
CHD risk was found, but not for studies that performed
regenotyping. Although overlapping confidence intervals for
before-mentioned risks indicate caution in any interpretations, no
report on blinding and regenotyping can point towards an
uncertainty in quality control of genotyping in these studies.
However, violation of HWE, which tends to inflate the chance of a
false positive association, may be the strongest indicator of
genotyping error [62].
Violation of HWE cannot solely explain the observed between-
study variation in gene-disease association studies. The large
between-study heterogeneity presented in most meta-analyses
could be due to true heterogeneity (i.e., racial differences or
differences in gene-environment interactions among various
populations) or bias [63]. Bias, which could invalidate the results
of the studies, should, therefore, be explored in detail. Biological
plausibility, publication bias, selection bias, biased definition of
cases, biased selection of controls, and population stratification
should be assessed [63]. In this meta-analysis, we found strong
evidence for publication bias. This is said to occur when the
chance of the publication of a smaller study increases when it
shows a stronger effect. Further exploration for sources of biases
among studies showed that the selection of controls was not biased.
However, using different case definitions resulted in a significant
difference in the risk of CHD between those studies using WHO
criteria and those using clinically diagnoses of CHD. Studies using
definition of cases based on coronary angiography or based on
WHO criteria had the same results. Considering a multivariate
model in the meta-regression results, case definition was not a
significant source of bias in the meta-analysis, while the different
Figure 4. Filled Begg’s funnel plot with pseudo 95% confidence limits under the additive genetic model. Red squares are missed
studies due to publication bias.
doi:10.1371/journal.pone.0002533.g004
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of heterogeneity. Since increasing age is a risk factor for CHD and
the mean age of cases in the included studies ranged from 42 to 67
years, it is more likely that the studies with older individuals would
show a stronger effect and produce heterogeneity. As case-parental
controls, or other family-based designs, and genomic controls,
using unlinked genetic markers which have no effect on the risk of
CHD, were not available to evaluate the potential problem of
population stratification among the studies, we presented effect
estimates by different ethnic groups. However, there is controversy
about the potential importance of population stratification for
genetic-association studies using unrelated subjects [64].
In conclusion, the present meta-analysis, including our own
data, indicated that, although a weak association between the
M235T variant in the AGT gene and CHD was found, the
relevance of this weakly positive overall association remains
uncertain because it may be due to various residual biases.
Moderate to large heterogeneity was identified between studies,
and violation of HWE and the mean age of cases were statistically
significant sources of the observed variation.
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